Sihuan (460 HK) Updates on Audit Delay: Improper accounting treatment in consolidation trick of using MRAs (Market Research Agents) to exclude hidden sales and distribution expenses to artificially boost profits

Related postings: Late audits halt trading in Morgan Stanley-backed stocks Tianhe Chemicals (1619 HK) and Sihuan Pharmaceutical (460 HK)

	Terence Chua on Potential Accounting Tunneling…
	Terence Chua on Potential Accounting Tunneling…
	Toshiba might have t… on Toshiba reportedly used accoun…
	Brittius on Deloitte Anjin is drawing crit…
	CS-Cart.com on Hanergy investigation could la…
	John Soh on Political Incentives to Suppre…
	Yunjung Hwang on Increase in debt at Hanjin Gro…
	bambooinnovator on Open Letter to SGX/MAS: Reply…
	Ong Peng on Open Letter to SGX/MAS: Reply…
	Anon on Zhongmin Baihui – Overva…
	terencechua8 on Potential Accounting Tunneling…
	bambooinnovator on Potential Accounting Tunneling…
	bambooinnovator on Open Letter to SGX/MAS: Reply…
	Anon on Zhongmin Baihui – Overva…
	bambooinnovator on Potential Accounting Tunneling…

AsianExtractor: Unearthing Accounting Fraud in Asia